Nootropil (Piracetam)

Piracetam acts by modulating neuronal membrane fluidity, enhancing AMPA‑receptor activity and facilitating calcium influx. These actions improve neuroplasticity, increase cerebral blood flow and promote more efficient neurotransmission, which together help to restore or improve cognitive and motor functions in affected brain regions.

The dosage of Nootropil is determined by the prescribing clinician based on the individual patient's condition, age, renal and hepatic function, and treatment goals. Specific dosing regimens are not publicly disclosed and should be obtained from a qualified healthcare professional.

Safety data for piracetam during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Consequently, it is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, as assessed by a physician.

To place an order, submit an enquiry on the Nootropil product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Piracetam is the prototype racetam and is generally considered to have a well‑established safety profile. Compared with newer racetams such as aniracetam or oxiracetam, piracetam is less lipophilic, often requiring intravenous administration, and may have a milder effect on cognition, but it remains widely used due to extensive clinical experience and regulatory acceptance.

Nootropil must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken vigorously. If the product is removed from controlled storage, it should be used promptly and any remaining volume discarded according to local regulations.

Nootropil is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically using a sterile infusion set. The rate and volume of infusion are determined by the prescribing physician based on the therapeutic indication and patient tolerance.

Serious adverse reactions, although rare, include allergic responses such as rash, pruritus or anaphylaxis, hematologic abnormalities like thrombocytopenia or leukopenia, and potential aggravation of seizure activity. Patients should be monitored for these events, and treatment should be discontinued if any serious reaction occurs.

Nootropil is contraindicated in patients with known hypersensitivity to piracetam or any excipients in the formulation. It should also be avoided in individuals with uncontrolled epilepsy, severe renal or hepatic impairment without appropriate monitoring, and in pregnant or breastfeeding women unless a physician determines that the benefits outweigh the risks.